| pubmed-article:14982803 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:14982803 | lifeskim:mentions | umls-concept:C1563238 | lld:lifeskim |
| pubmed-article:14982803 | lifeskim:mentions | umls-concept:C0441655 | lld:lifeskim |
| pubmed-article:14982803 | lifeskim:mentions | umls-concept:C1260298 | lld:lifeskim |
| pubmed-article:14982803 | lifeskim:mentions | umls-concept:C1533691 | lld:lifeskim |
| pubmed-article:14982803 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:14982803 | pubmed:dateCreated | 2004-2-25 | lld:pubmed |
| pubmed-article:14982803 | pubmed:abstractText | The in vitro activities of tigecycline were tested against 831 isolates of the Bacteroides fragilis group representing all of the species within the group. On a weight-to-weight basis (8 microg/ml), tigecycline was more active than clindamycin, minocycline, trovafloxacin, and cefoxitin and less active than imipenem or piperacillin-tazobactam against all isolates of the B. fragilis group. Tigecycline geometric mean MICs were statistically higher against B. distasonis than other Bacteroides species (P value of 0.0001). | lld:pubmed |
| pubmed-article:14982803 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14982803 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14982803 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14982803 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14982803 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14982803 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14982803 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14982803 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14982803 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14982803 | pubmed:language | eng | lld:pubmed |
| pubmed-article:14982803 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14982803 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:14982803 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14982803 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14982803 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14982803 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:14982803 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:14982803 | pubmed:issn | 0066-4804 | lld:pubmed |
| pubmed-article:14982803 | pubmed:author | pubmed-author:SnydmanD RDR | lld:pubmed |
| pubmed-article:14982803 | pubmed:author | pubmed-author:JacobusN VNV | lld:pubmed |
| pubmed-article:14982803 | pubmed:author | pubmed-author:RuthazerRR | lld:pubmed |
| pubmed-article:14982803 | pubmed:author | pubmed-author:McDermottL... | lld:pubmed |
| pubmed-article:14982803 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:14982803 | pubmed:volume | 48 | lld:pubmed |
| pubmed-article:14982803 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:14982803 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:14982803 | pubmed:pagination | 1034-6 | lld:pubmed |
| pubmed-article:14982803 | pubmed:dateRevised | 2009-11-18 | lld:pubmed |
| pubmed-article:14982803 | pubmed:meshHeading | pubmed-meshheading:14982803... | lld:pubmed |
| pubmed-article:14982803 | pubmed:meshHeading | pubmed-meshheading:14982803... | lld:pubmed |
| pubmed-article:14982803 | pubmed:meshHeading | pubmed-meshheading:14982803... | lld:pubmed |
| pubmed-article:14982803 | pubmed:meshHeading | pubmed-meshheading:14982803... | lld:pubmed |
| pubmed-article:14982803 | pubmed:meshHeading | pubmed-meshheading:14982803... | lld:pubmed |
| pubmed-article:14982803 | pubmed:year | 2004 | lld:pubmed |
| pubmed-article:14982803 | pubmed:articleTitle | In vitro activities of tigecycline against the Bacteroides fragilis group. | lld:pubmed |
| pubmed-article:14982803 | pubmed:affiliation | Department of Medicine, Tufts-New England Medical Center, Boston, Massachusetts 02111, USA. | lld:pubmed |
| pubmed-article:14982803 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:14982803 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14982803 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14982803 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14982803 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14982803 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14982803 | lld:pubmed |
